Articles

Results from the MONALEESA trials show that PFS benefit with ribociclib in combination with endocrine therapy found to be consistent regardless of expression levels of most cell cycle genes. Read More ›

Analysis from the MONALEESA and RIBANNA trials in patients with HR-positive/HER2-negative advanced breast cancer finds differences in PFS among patients treated with ribociclib in combination with endocrine therapy among MONALEESA-like subgroups. Read More ›

An overview of recently passed legislation and proposals anticipated in the coming year Read More ›

A comprehensive review of the role of prescriber feedback reports in managing drug utilization Read More ›

Session exploring the roles of community engagement, clinical trials, and formulary management in addressing health disparities Read More ›

In patients with relapsed or refractory LBCL treated with lisocabtagene maraleucel, post-infusion monitoring costs were lower in the outpatient setting versus the inpatient setting Read More ›

Survey finds that the majority of patients were in favor of or indifferent to treatment in the inpatient setting if better outcomes could be achieved Read More ›

Survey of healthcare decision makers found that preapproval information exchange could have a positive impact on shortening formulary decision-making timelines Read More ›

Multi-cancer early detection screening can achieve better cancer detection and comparable or improved cost-effectiveness Read More ›

Study utilizing an epidemiological model estimates the incidence of DLBCL and evaluates treatment patterns by line of therapy Read More ›